Follow
Meenakshi Srinivasan
Meenakshi Srinivasan
Verified email at gsk.com
Title
Cited by
Cited by
Year
Xenobiotic metabolism and gut microbiomes
A Das, M Srinivasan, TS Ghosh, SS Mande
PloS one 11 (10), e0163099, 2016
712016
Comparison of various severity assessment scoring systems in patients with sepsis in a tertiary care teaching hospital
K Badrinath, M Shekhar, M Sreelakshmi, M Srinivasan, G Thunga, S Nair, ...
Indian journal of critical care medicine: peer-reviewed, official …, 2018
312018
Diversity in the era of precision medicine-from bench to bedside implementation
A Mamun, NY Nsiah, M Srinivasan, A Chaturvedula, R Basha, D Cross, ...
Ethnicity & disease 29 (3), 517, 2019
162019
Pharmacokinetic potentiation of mixed organophosphate and pyrethroid poison leading to prolonged delayed neuropathy
M Srinivasan, R Amin, G Thunga, SK Nagiri, CU Kudru
Journal of clinical and diagnostic research: JCDR 10 (11), FD01, 2016
122016
Incorporating pharmacometrics into pharmacoeconomic models: applications from drug development
M Srinivasan, A White, A Chaturvedula, V Vozmediano, S Schmidt, ...
Pharmacoeconomics 38, 1031-1042, 2020
112020
Comparison of the Nosocomial Pneumonia Mortality Prediction (NPMP) model with standard mortality prediction tools
M Srinivasan, N Shetty, S Gadekari, G Thunga, K Rao, V Kunhikatta
Journal of Hospital Infection 96 (3), 250-255, 2017
92017
Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects
C Tiffany, EF Dumont, M Hossain, M Srinivasan, B Swift
Clinical and Translational Science 15 (9), 2251-2264, 2022
62022
Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs
S Anderson, J Mauskopf, SE Talbird, A White, M Srinivasan
Epilepsy & Behavior 125, 108368, 2021
62021
Development of a pharmacoeconomic registry: an example using hormonal contraceptives
A White, M Srinivasan, LM Wingate, S Peasah, M Fleming
Health Economics Review 11, 1-20, 2021
52021
The Nosocomial Pneumonia Mortality Prediction (NPMP) model–a tool to predict mortality in patients with nosocomial pneumonia
V Kunhikatta, M Srinivasan, G Thunga, NR Rau, AN Nagappa
Indian Journal of Medical Specialities 8 (1), 21-24, 2017
42017
Utility of Physiologically Based Pharmacokinetic Modeling in Point-of-Care Decisions: An Example Using Digoxin Dosing in Continuous Venovenous Hemodiafiltration
M Srinivasan, R Hirani, M Tsiu, K Kabani, A Chaturvedula, B Palasik
Therapeutic Drug Monitoring 42 (1), 1-5, 2020
32020
Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transporters
A Barth, CR Perry, S Shabbir, MJ Zamek‐Gliszczynski, S Thomas, ...
Clinical and Translational Science 16 (4), 647-661, 2023
22023
Pharmacokinetic, safety, and tolerability evaluations of gepotidacin (GSK2140944) in healthy Japanese participants
A Barth, M Hossain, CR Perry, AS Gross, H Ogura, S Shabbir, S Thomas, ...
Clinical Pharmacology in Drug Development 12 (1), 38-56, 2023
22023
Population Pharmacokinetics of Pemetrexed in Adult Non–Small Cell Lung Cancer in Indian Patients
M Srinivasan, A Chaturvedula, MJ Fossler, A Patil, V Gota, K Prabhash
The Journal of Clinical Pharmacology 59 (9), 1216-1224, 2019
22019
Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients
VG Meenakshi Srinivasan, Ayyappa Chaturvedula, Michael J. Fossler, Anand ...
Ninth American Conference on Pharmacometrics (ACoP9), 45 (S1), https://link …, 2018
2*2018
Identification of potential risk factors for the poor prognosis of neonatal sepsis
P Sahu, M Srinivasan, G Thunga, LE Lewis, V Kunhikatta
Medicine and Pharmacy Reports 95 (3), 282, 2022
12022
Outcomes and economic burden of hormonal contraceptive failure in developing countries: A case for improving effectiveness?
M Srinivasan, A White
12019
Evaluation of the Sensitivity of Concluding Bioequivalence Using Stochastic Simulation and Estimation
K Fairman, A Chaturvedula, M Srinivasan
12018
PIH9 BUDGET IMPACT ANALYSIS VS. COST EFFECTIVENESS ANALYSIS-HORMONAL CONTRACEPTIVES AS AN ILLUSTRATIVE CASE
JDK Nzia, A White, M Srinivasan
Value in Health 23, S152, 2020
2020
PIH13 COST IMPLICATIONS OF DRUG-DRUG INTERACTIONS WITH HORMONAL CONTRACEPTIVES: A CONCEPTUAL FRAMEWORK BASED ON LINKED PHARMACOKINETIC-PHARMACODYNAMIC-PHARMACOECONOMIC (PK-PD …
M Srinivasan, A White, A Chaturvedula, S Schmidt, G Adunlin, LT Wingate
Value in Health 22, S184-S185, 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–20